Safety & Tolerability of a Medicinal CBD

for Patients with Chronic Pain

This phase I open-label study, published in the Pain and Therapy journal examined pharmacokinetics, safety, and tolerability of escalating doses of a novel combination cannabinoid medication (1:1 tetrahydrocannabinol [THC]/cannabidiol [CBD]) in patients with chronic non-cancer pain (CNCP) on high dose opioid analgesia.